Thank you Siddhartha Mukherjee for taking the time out of your busy schedule to visit Swanton Lab Will Hill Clare Weeden Charles Swanton to talk about our work on air pollution and lung cancer The Francis Crick Institute

Absolutely stoked that 'Bug in the System: The past, present and future of cancer' has been picked up for Seriously - always a must-listen in my podcast app. Check out all 3 episodes here: bbc.co.uk/programmes/m00… #scicomm #cancer #cancerresearch #immunotherapy

Come start your group at the Crick! 💡 We're looking for creative early career researchers in cardiac and vascular biology, or clinician scientists in any field, to join our faculty community. #AcademicJobs | #ECRChat Apply by 5 October ⬇️ crick.ac.uk/careers-study/…

It has been great to collaborate with Hannah Greenwood, Tim Witney and team on their investigation of a new PET-based approach for imaging NRF2 activation in NSCLC. A tour de force across cell lines, GEMMs and CRUK Lung Centre PDX models!

Extremely grateful and excited to have support from Science and Innovation at Cancer Research UK to work on cancer initiation with Swanton Lab The Francis Crick Institute! Ever grateful to Jayant K. Rane Alex Frankell for the supervision and mentorship

Patient-derived xenograft (PDX) models allow cancer researchers to study tumour tissue from patients in mice. Our CRUK Lung Centre paper Nature Communications describes 48 new PDX models and highlights the importance of intratumor heterogeneity in the development of cancer models (1/9)

My Swanton Lab postdoc paper is now out Nature Communications. It was a huge privilege to work with the TRACERx team. Thanks to Ariana Huebner and Dave Pearce, as well as everyone else UCL Cancer Institute, The Francis Crick Institute and CRUK Manchester Institute who made this happen.

Patient-derived xenograft (PDX) models are widely used and valuable tools in #CancerResearch. But there are limitations to how well these models can represent the genetic complexity of patient tumours Rob Hynds Swanton Lab buff.ly/4aNLqDh Science and Innovation at Cancer Research UK The Francis Crick Institute UCL News

This study highlights the importance of considering primary tumor heterogeneity when using PDX models and emphasizes the benefit of comprehensive tumor sampling nature.com/articles/s4146…

New review out in Trends in Cancer from Chris Abbosh and Charles Swanton. Excellent summary of latest evidence & use case for ctDNA in NSCLC at diagnosis/landmark timepoints to help with staging and decisions around adjuvant treatment - worth reading #LCSM sciencedirect.com/science/articl…

Comment: Capturing heterogeneity in PDX models: representation matters nature.com/articles/s4146…

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in Nature Communications. nature.com/articles/s4146… 🧵

Today our study of the association between replication timing alterations and mutation acquisition during cancer evolution has been published in Nature Communications nature.com/articles/s4146…

Is Osimertinib over? Not at all IMO. We just need to think more deeply about patient selection. I’ll point (again) to our recent paper looking at Genome Doubling and TP53 in EGFR positive NSCLC with @swantonlab nature.com/articles/s4146…

Our TRACERx non-small cell lung cancer (NSCLC) patient-derived-xenograft (PDX) models are now available through CancerTools.org 🎉 A big thank you to Dave Pearce and the incredible CRUK Lung Centre team who have made this possible!

🚨So proud to present the first study from our Computational Cancer Genomics (CCG) Research Group group together with Charles Swanton Nnennaya Kanu and led by Olivia Lucas with key collaboration Sophie Ward and fundamental support Rija Zaidi Abi Bunkum & many others Out in Nature Genetics 👇 doi.org/10.1038/s41588… 🧵👇

Great to see this collaborative paper out Nature Communications. Tim Witney's team developed a PET radiotracer that distinguishes high/low NRF2 antioxidant pathway activation, including in our CRUK Lung Centre PDX models. Congrats Hannah Greenwood and team! 👏 nature.com/articles/s4146…

CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises the risk of hematological malignancies, chronic inflammatory diseases (like heart & lung disease), & lung cancer. This manuscript shows that CHIP somatic

Excited to share our new paper with Sheila's lab: we performed an in vivo genome-wide CRISPRa screen using a lung TRACERx PDX model to uncover drivers of brain metastasis. BACE1 emerged as a key hit - especially interesting given ongoing therapeutic efforts in Alzheimer’s.

Online Now: Subclonal immune evasion in non-small cell lung cancer dlvr.it/TLkxG2